Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Wurst

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
International Journal of Clinical Pharmacology, Therapy, and Toxicology|November 1, 1992
Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?H Bliesath, B Simon, M Hartmann, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1996
Lack of pharmacokinetic interaction between pantoprazole and diclofenacH Bliesath, R Huber, V W Steinijans, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1996
Pantoprazole does not interact with nifedipine in man under steady-state conditionsH Bliesath, R Huber, V W Steinijans, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 1, 1996
Lack of pharmacokinetic interaction between pantoprazole and diclofenacH Bliesath, R Huber, V W Steinijans, et al.
Alimentary Pharmacology & Therapeutics|June 1, 1990
Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in manB Simon, P Müller, H Bliesath, et al.
Clinical Drug Investigation|March 29, 2008
Pantoprazole does not affect performance in traffic-related safety tests: a double-blind, randomised, placebo-controlled, crossover study in healthy volunteersK W Herberg, M Hartmann, B Neukirchen, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 30, 2001
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administrationT H Bethke, M Merz, K Zech, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 11, 1999
Pantoprazole lacks induction of CYP1A2 activity in manM Hartmann, K Zech, H Bliesath, et al.
The Journal of Investigative Dermatology|October 3, 1999
Regulation of epidermal bullous pemphigoid antigen 1 (BPAG1) synthesis by homeoprotein transcription factorsG Mainguy, H Ernø, M L Montesinos, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trialD Ukena, C Boewer, B Oldenkott, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
International Journal of Clinical Pharmacology, Therapy, and Toxicology|November 1, 1992
Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?H Bliesath, B Simon, M Hartmann, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1996
Lack of pharmacokinetic interaction between pantoprazole and diclofenacH Bliesath, R Huber, V W Steinijans, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1996
Pantoprazole does not interact with nifedipine in man under steady-state conditionsH Bliesath, R Huber, V W Steinijans, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 1, 1996
Lack of pharmacokinetic interaction between pantoprazole and diclofenacH Bliesath, R Huber, V W Steinijans, et al.
Alimentary Pharmacology & Therapeutics|June 1, 1990
Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in manB Simon, P Müller, H Bliesath, et al.
Clinical Drug Investigation|March 29, 2008
Pantoprazole does not affect performance in traffic-related safety tests: a double-blind, randomised, placebo-controlled, crossover study in healthy volunteersK W Herberg, M Hartmann, B Neukirchen, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 30, 2001
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administrationT H Bethke, M Merz, K Zech, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 11, 1999
Pantoprazole lacks induction of CYP1A2 activity in manM Hartmann, K Zech, H Bliesath, et al.
The Journal of Investigative Dermatology|October 3, 1999
Regulation of epidermal bullous pemphigoid antigen 1 (BPAG1) synthesis by homeoprotein transcription factorsG Mainguy, H Ernø, M L Montesinos, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trialD Ukena, C Boewer, B Oldenkott, et al.
Pageof 14